BitMEX co-founder Arthur Hayes stated that the divergence between Bitcoin (BTC) and the Nasdaq 100 could push the price below $60,000. Continue Reading: BitMEXBitMEX co-founder Arthur Hayes stated that the divergence between Bitcoin (BTC) and the Nasdaq 100 could push the price below $60,000. Continue Reading: BitMEX

BitMEX Founder Arthur Hayes Issues Serious Warning to Investors Regarding Bitcoin (BTC) Price!

2026/02/18 17:39
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Arthur Hayes, co-founder of BitMEX, who has made a name for himself with his statements about Bitcoin and the cryptocurrency market, has revealed his latest predictions.

Arthur Hayes stated that the divergence between Bitcoin and the Nasdaq 100 could pull the price below $60,000.

Arthur Hayes predicts that Bitcoin could fall below $60,000 due to the increasing divergence from the Nasdaq 100 and dwindling global liquidity.

In his latest blog post, Hayes noted that Bitcoin has experienced a sharp correction since reaching its all-time high in October 2025, while the Nasdaq 100 has remained relatively stable.

Hayes argues that this disparity stems from job losses due to advances in artificial intelligence, and that this signals an impending dollar credit crunch.

At this point, some analysts have also noted that this situation is seen as Bitcoin pricing in the risk of a dollar-based credit crunch or credit deflation. If this credit deflation intensifies, the Fed may initiate large-scale liquidity injections that could mirror the monetary easing policies seen after the 2008 global financial crisis.

Hayes outlined two possible scenarios. In the first scenario, Bitcoin’s correction is already complete, and Nasdaq will fall independently to restore balance.

In the second scenario, a sharp drop in the Nasdaq could pull Bitcoin below $60,000 before a recovery supported by the Fed’s liquidity measures.

At this point, Hayes advised investors to adopt a cautious approach by reducing excessive leverage and increasing their cash reserves.

*This is not investment advice.

Continue Reading: BitMEX Founder Arthur Hayes Issues Serious Warning to Investors Regarding Bitcoin (BTC) Price!

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$73.016,87
$73.016,87$73.016,87
-%0,85
USD
Bitcoin (BTC) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage